Home>Topics>Stocks>Hologic

Hologic HOLX

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Insulet names new chief, reiterates revenue guidance

      Headlines

      Tue, 16 Sep 2014

      CEO replacing the retiring Duance DeSisto. Mr. Sullivan was the former CEO of Cytyc Corp. and the Executive Chairman of Hologic after it acquired Cytyc. The company reiterates its revenue guidance: $73M - 77M for Q3 and $290M - 300M for 2014. Post

    2. GE wins FDA approval for 3D mammography device

      Headlines

      Wed, 3 Sep 2014

      mammography device that produces 3D images to detect breast cancer, adding new competition to the market dominated by Hologic (NASDAQ: HOLX ). The 3D mammography device contains hardware and software upgrades to the company's previously launched Senographe

    3. Hologic Looks To Be A Solid Play, With Carl Icahn Owning 12.3%

      Headlines

      Thu, 28 Aug 2014

      By Asean Century : Hologic (NASDAQ: HOLX ) peaked my interest when I read ..... was also surprised to find that Hologic has been serving the women's health ..... traded for 24 of those years. Hologic describes itself as "a leading

    4. New Morningstar Analyst Report for Hologic Inc

      Stock Reports

      Mon, 25 Aug 2014

      market is in secular decline and could weigh on Hologic ’s results beyond 2014 should it take longer ..... for breast tomosynthesis will be lucrative for Hologic ’s customers.Despite Hologic ’s full pipeline and best efforts, a high degree

    5. New Morningstar Analyst Report for Abbott Laboratories

      Stock Reports

      Mon, 25 Aug 2014

      diagnostics arena where it must go head-to-head against market leader Roche, along with energetic upstarts like Qiagen and Hologic .Considering the heterogeneity involved in mitral valve disease, we are skeptical MitraClip will move beyond niche use for

    6. Tracking Carl Icahn's Portfolio - Q2 2014 Update

      Headlines

      Tue, 19 Aug 2014

      By John Vincent : This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn's US stock portfolio on a quarterly basis. It is based on Icahn's regulatory 13F Form filed on 08/14/2014. Please visit our Tracking Carl Icahn's Portfolio series to get an idea of

    7. Markman hearing today regarding Enzo Biochem patents

      Headlines

      Mon, 18 Aug 2014

      important event in patent litigation. The company has outstanding patent disputes with Abbott Labs, Affymetrix, Agilent, Becton Dickinson, Gen-Probe, Hologic , Ilumina, Life Technologies, Luminex, Roche and Seimens. Post your comment!

    8. Hologic Remains Afloat as Key Franchises Offset Sluggish ThinPrep Volume

      Commentary

      Thu, 31 Jul 2014

      Hologic released strong third-quarter results on ..... stable trend ratings also remain intact. Hologic ’s third-quarter revenue increased by ..... continues to expand. On the cost side, Hologic ’s adjusted gross margin increased by

    9. New Study on 3D Mammography Reinforces Our Views on Hologic ’s Breast Health Franchise

      Commentary

      Thu, 26 Jun 2014

      Hologic made a number of headlines on June 25 with ..... narrow moat and stable trend ratings for Hologic remain intact, and we plan to maintain our ..... falling within U.S. guidelines. However, Hologic ’s rollout of its recently approved C

    10. Hologic Garners Sales Momentum in Second Quarter

      Commentary

      Thu, 1 May 2014

      Hologic reported improved second-quarter earnings ..... to continued strength in the uptake of Hologic ’s 3D mammography equipment. While the company ..... Panther systems remains encouraging, and Hologic appears capable of installing 1,000 units

    « Prev12345Next »
    Content Partners